Global Radiation Toxicity Therapeutics 麻豆原创 Research Report 2023

Publication ID:

PB510230429

Publication Date:

October 19, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Treatment听of acute听radiation听syndrome is generally supportive care. This may include blood transfusions, antibiotics, colony-stimulating factors, or stem cell transplant. If radioactive material remains on the skin or in the stomach it should be removed.
The global Radiation Toxicity Therapeutics market is projected to reach US$ 5591.9 million in 2029, increasing from US$ 3762 million in 2022, with the CAGR of 5.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Radiation Toxicity Therapeutics market research.
The radiation toxicity treatment market is driven by the increasing use of radiation therapy in cancer treatment and the growing number of nuclear accidents and incidents. Radiation therapy is a critical component in cancer treatment, but it can lead to radiation toxicity, causing various side effects in patients. As the number of cancer cases rises, the demand for radiation therapy is also increasing, consequently driving the need for effective radiation toxicity treatments. Additionally, nuclear accidents and incidents, such as nuclear power plant disasters and radiation exposure from accidents or terrorism, highlight the importance of developing treatments for radiation toxicity. However, the challenge lies in developing treatments that effectively mitigate the harmful effects of radiation while minimizing side effects. Additionally, regulatory approvals and safety concerns are significant challenges in bringing radiation toxicity treatments to the market. Collaborative research efforts and advancements in medical technology are vital in addressing these challenges and providing safer and more effective radiation toxicity treatments.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Radiation Toxicity Therapeutics market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Amgen
Partner Therapeutics
Novartis
Viatris
Coherus BioSciences
Jubilant Life Sciences
Siegfried Holdings
Recipharm AB
Mission Pharmacal Company
Segment by Type
Ionizing Radiation
Non-ionizing Radiation
Segment by Application
Hospital
Research & Academic Institutes
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Radiation Toxicity Therapeutics report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Radiation Toxicity Therapeutics 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Ionizing Radiation
1.2.3 Non-ionizing Radiation
1.3 麻豆原创 by Application
1.3.1 Global Radiation Toxicity Therapeutics 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Research & Academic Institutes
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radiation Toxicity Therapeutics 麻豆原创 Perspective (2018-2029)
2.2 Radiation Toxicity Therapeutics Growth Trends by Region
2.2.1 Global Radiation Toxicity Therapeutics 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Radiation Toxicity Therapeutics Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Radiation Toxicity Therapeutics Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Radiation Toxicity Therapeutics 麻豆原创 Dynamics
2.3.1 Radiation Toxicity Therapeutics Industry Trends
2.3.2 Radiation Toxicity Therapeutics 麻豆原创 Drivers
2.3.3 Radiation Toxicity Therapeutics 麻豆原创 Challenges
2.3.4 Radiation Toxicity Therapeutics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radiation Toxicity Therapeutics Players by Revenue
3.1.1 Global Top Radiation Toxicity Therapeutics Players by Revenue (2018-2023)
3.1.2 Global Radiation Toxicity Therapeutics Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Radiation Toxicity Therapeutics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radiation Toxicity Therapeutics Revenue
3.4 Global Radiation Toxicity Therapeutics 麻豆原创 Concentration Ratio
3.4.1 Global Radiation Toxicity Therapeutics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radiation Toxicity Therapeutics Revenue in 2022
3.5 Radiation Toxicity Therapeutics Key Players Head office and Area Served
3.6 Key Players Radiation Toxicity Therapeutics Product Solution and Service
3.7 Date of Enter into Radiation Toxicity Therapeutics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Radiation Toxicity Therapeutics Breakdown Data by Type
4.1 Global Radiation Toxicity Therapeutics Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Radiation Toxicity Therapeutics Forecasted 麻豆原创 Size by Type (2024-2029)
5 Radiation Toxicity Therapeutics Breakdown Data by Application
5.1 Global Radiation Toxicity Therapeutics Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Radiation Toxicity Therapeutics Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Radiation Toxicity Therapeutics 麻豆原创 Size (2018-2029)
6.2 North America Radiation Toxicity Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Radiation Toxicity Therapeutics 麻豆原创 Size by Country (2018-2023)
6.4 North America Radiation Toxicity Therapeutics 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radiation Toxicity Therapeutics 麻豆原创 Size (2018-2029)
7.2 Europe Radiation Toxicity Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Radiation Toxicity Therapeutics 麻豆原创 Size by Country (2018-2023)
7.4 Europe Radiation Toxicity Therapeutics 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radiation Toxicity Therapeutics 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Radiation Toxicity Therapeutics 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Radiation Toxicity Therapeutics 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Radiation Toxicity Therapeutics 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radiation Toxicity Therapeutics 麻豆原创 Size (2018-2029)
9.2 Latin America Radiation Toxicity Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Radiation Toxicity Therapeutics 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Radiation Toxicity Therapeutics 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radiation Toxicity Therapeutics 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Radiation Toxicity Therapeutics 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Radiation Toxicity Therapeutics 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Radiation Toxicity Therapeutics 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Radiation Toxicity Therapeutics Introduction
11.1.4 Amgen Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.1.5 Amgen Recent Development
11.2 Partner Therapeutics
11.2.1 Partner Therapeutics Company Detail
11.2.2 Partner Therapeutics Business Overview
11.2.3 Partner Therapeutics Radiation Toxicity Therapeutics Introduction
11.2.4 Partner Therapeutics Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.2.5 Partner Therapeutics Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Radiation Toxicity Therapeutics Introduction
11.3.4 Novartis Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Viatris
11.4.1 Viatris Company Detail
11.4.2 Viatris Business Overview
11.4.3 Viatris Radiation Toxicity Therapeutics Introduction
11.4.4 Viatris Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.4.5 Viatris Recent Development
11.5 Coherus BioSciences
11.5.1 Coherus BioSciences Company Detail
11.5.2 Coherus BioSciences Business Overview
11.5.3 Coherus BioSciences Radiation Toxicity Therapeutics Introduction
11.5.4 Coherus BioSciences Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.5.5 Coherus BioSciences Recent Development
11.6 Jubilant Life Sciences
11.6.1 Jubilant Life Sciences Company Detail
11.6.2 Jubilant Life Sciences Business Overview
11.6.3 Jubilant Life Sciences Radiation Toxicity Therapeutics Introduction
11.6.4 Jubilant Life Sciences Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.6.5 Jubilant Life Sciences Recent Development
11.7 Siegfried Holdings
11.7.1 Siegfried Holdings Company Detail
11.7.2 Siegfried Holdings Business Overview
11.7.3 Siegfried Holdings Radiation Toxicity Therapeutics Introduction
11.7.4 Siegfried Holdings Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.7.5 Siegfried Holdings Recent Development
11.8 Recipharm AB
11.8.1 Recipharm AB Company Detail
11.8.2 Recipharm AB Business Overview
11.8.3 Recipharm AB Radiation Toxicity Therapeutics Introduction
11.8.4 Recipharm AB Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.8.5 Recipharm AB Recent Development
11.9 Mission Pharmacal Company
11.9.1 Mission Pharmacal Company Company Detail
11.9.2 Mission Pharmacal Company Business Overview
11.9.3 Mission Pharmacal Company Radiation Toxicity Therapeutics Introduction
11.9.4 Mission Pharmacal Company Revenue in Radiation Toxicity Therapeutics Business (2018-2023)
11.9.5 Mission Pharmacal Company Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Amgen
Partner Therapeutics
Novartis
Viatris
Coherus BioSciences
Jubilant Life Sciences
Siegfried Holdings
Recipharm AB
Mission Pharmacal Company

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.